

# CITATION REPORT

List of articles citing

Comparative assessment of pharmacokinetics, and pharmacodynamics between RTX83(TM) rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

DOI: 10.1007/s00280-018-3524-9

Cancer Chemotherapy and Pharmacology, 2018, 81, 515-527.

Source: <https://exaly.com/paper-pdf/69121822/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. <i>MABs</i> , <b>2018</b> , 10, 827-842	6.6	3
28	Biosimilar drugs: how safe are they?. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3343-3344	1.9	1
27	Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies. <i>AAPS Journal</i> , <b>2019</b> , 21, 85	3.7	0
26	Rituximab biosimilar RTX83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3375-3385	1.9	11
25	Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. <i>American Journal of Health-System Pharmacy</i> , <b>2019</b> , 76, 1725-1738	2.2	9
24	Rituximab biosimilars for lymphoma in Europe. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 1045-1056	5.4	5
23	Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2002-2010	3.8	10
22	Physicochemical and Biological Characterization of RTX83, a New Rituximab Biosimilar. <i>BioDrugs</i> , <b>2019</b> , 33, 307-319	7.9	12
21	Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Global Oncology</i> , <b>2019</b> , 5, 1-13	2.6	10
20	Biosimilar medicines used for cancer therapy in Europe: a review. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 293-299	8	17
19	Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy. <i>Annals of Pharmacotherapy</i> , <b>2019</b> , 53, 357-363	2.9	12
18	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 519-530	6.2	5
17	Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin) in patients with advanced non-squamous non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 487-499	3.5	2
16	Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20 B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study. <i>Scientific Reports</i> , <b>2020</b> , 10, 11676	4.9	2
15	Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 513-524	6.1	1
14	Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea. <i>Applied Health Economics and Health Policy</i> , <b>2020</b> , 18, 557-566	3.4	4
13	Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. <i>Acta Pharmacologica Sinica</i> , <b>2021</b> , 42, 641-647	8	3

12	Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. <i>Future Oncology</i> , <b>2021</b> , 17, 2529-2544	3.6	3
11	Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 725665	5.6	0
10	The Influence of Different Disease States on Rituximab Pharmacokinetics. <i>Current Drug Metabolism</i> , <b>2020</b> , 21, 938-946	3.5	4
9	Efficacy and safety of biosimilar rituximab (Zytux <sup>TM</sup> ) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Hematology Reports</i> , <b>2020</b> , 12, 8296	0.9	1
8	The challenges of developing and commercializing biosimilars in Latin America. <i>Pharmaceutical Patent Analyst</i> , <b>2019</b> , 8, 221-224	0.6	1
7	Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	2
6	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 1	6.2	0
5	Biosimilar Monoclonal Antibodies in Latin America.		
4	Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study. <i>EClinicalMedicine</i> , <b>2021</b> , 42, 101187 <sup>1.3</sup>		2
3	Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. <b>2022</b> , 155, 335		0
2	Rituximab PK and PKPD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity.		0
1	Intra-articular Injection of a B Cell Depletion Antibody Enhances Local Exposure to the Joint-Draining Lymph Node in Mice with Collagen-Induced Arthritis. <b>2023</b> , 20, 2053-2066		0